Barlesi, F., Steins, M., Horn, L., Ready, N., Felip, E., Borghaei, H., … Paz-Ares, L. (2016). Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. In Annals of Oncology (Vol. 27, p. vi420). https://doi.org/10.1093/annonc/mdw383.15

Barlesi, F., M. Steins, L. Horn, N. Ready, E. Felip, H. Borghaei, D. R. Spigel, et al. “Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update.” In Annals of Oncology, 27:vi420, 2016. https://doi.org/10.1093/annonc/mdw383.15.

Barlesi F, Steins M, Horn L, Ready N, Felip E, Borghaei H, et al. Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. In: Annals of Oncology. 2016. p. vi420.

Barlesi, F., et al. “Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update.” Annals of Oncology, vol. 27, 2016, p. vi420. Scopus, doi:10.1093/annonc/mdw383.15.

Barlesi F, Steins M, Horn L, Ready N, Felip E, Borghaei H, Spigel DR, Arrieta O, Antonia SJ, Fayette J, Rizvi N, Crinò L, Reck M, Eberhardt WE, Hellmann M, Geese WJ, Li A, Healey D, Brahmer JR, Paz-Ares L. Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. Annals of Oncology. 2016. p. vi420.